Gain Strategic Insights by Linking Clinical Trial Data to Real World Data

Randomized clinical trials (RTCs) are the cornerstone of medical research, however traditional RTCs often face limitations.  Download our white paper Gain Strategic Insights by Linking Clinical Trial Data to Real World Data for perspective on the broader, deeper insights that can be gained about clinical trial patients through tokenization and real-world data enrichment/linkage.  Here we describe:

• Insights that can be gained from RWD enrichment/linkage   
• The tokenization process
• The importance of data standardization for generating accurate results from linked RWD analyses
• A case study, where a sponsor partners with UBC to enrich a clinical trial with RWD

The FDA and other regulatory agencies recognize the value of RWD/RWE in drug development and approval processes. Our white paper details FDA guidelines and offers best practices for integrating RWD into your clinical trials.

UBC’s Irene Cosmatos, Senior Director, Epidemiology, and Judy Lytle, PhD, MBEE, PMP, Executive Director, Evidence Development Study Solutions, explore how integrating RWD/RWE with clinical trial data can overcome challenges, providing comprehensive insights, and enhancing regulatory submissions. Read our white paper to learn more about how these approaches can transform your research and regulatory submissions.

Get started by completing the form to access our white paper: Gain Strategic Insights by Linking Clinical Trial Data to Real World Data.